SciSparc Ltd SPRC shares are trading higher Wednesday after the company announced positive results from the Phase IIa clinical trial of its investigational compound for the treatment of agitation in elderly Alzheimer's patients.
The Details:
SciSparc announced positive topline results from the Phase IIa trial of its SCI-110 drug candidate at the Sophie & Abraham Stuchynski Israeli Alzheimer's Medical Center (IMCA). The company reported that results met primary endpoints regarding tolerability and adverse events and demonstrated SCI-110's potential to alleviate agitation without side effects.
"We are thrilled with these outcomes, as they signify a monumental potential in enhancing the lives of AD patients. Our commitment to pioneering innovative treatments with a global impact has never been clearer," said Dr. Adi Zuloff- Shani, CTO of SciSparc.
SPRC shares are soaring on high volume as investors react to the positive trial results. According to data from Benzinga Pro, more than 10.55 million shares have been traded in the session, compared to the stock's 100-day average volume of 1.181 million shares.
Notably, SciSparc Ltd.'s stock has a small float of just over 523 thousand shares.
Related News: What's Going On With Plug Power Stock Today?
SPRC Price Action: According to Benzinga Pro, SciSparc shares are up 58% at $6.87 at the time of publication.
Image: 506967 from Pixabay
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
